AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$HAE

Haemonetics advances 17% on CSL supply deal (HAE:NYSE)

Haemonetics (HAE) rose 17% to a 52-week high after announcing a plasma supply agreement with CSL. The stock closed at $119.47, up $17.76.

Original reporting
seekingalpha.com
Published Oct 8, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Haemonetics advances 17% on CSL supply deal (HAE:NYSE) — source image
Source · seekingalpha.com
Decision brief

The 30-second read

$HAEBullishLow
01

Why it matters

The newly announced non‑exclusive plasma supply agreement with CSL triggered a 17% intraday rally in Haemonetics shares, reflecting market optimism about added revenue streams.

02

Market read

Contract news sparked a sharp rally, highlighting the importance of supply agreements in the plasma market.

03

What to watch

Deal size and duration are undisclosed; execution risk and competition could affect long‑term benefit.

Relevance 8/10Novelty 8/10Timing: after market close

Background

Haemonetics is a medical‑technology company focused on blood management; CSL is a global biotech specializing in plasma products.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Haemonetics disclosed a non‑exclusive plasma supply agreement with CSL, sending the stock up 17% to a 52‑week high.

Expected impact

likely pressure as the market prices in the supply deal, but limited upside after sharp move

Evidence & confidence

Deal adds revenue potential but price already jumped, so further gains may be constrained.

Market effects

Sector

Boosts plasma collection and blood‑management sector, may benefit related suppliers.

Regional

Positive sentiment in US healthcare equities following the contract news.

Global

Limited global impact; CSL is an Australian biotech but the deal influences worldwide plasma supply dynamics.

Counterpoint

What could challenge this read

The 17% rally may be overdone; further upside limited after the sharp move.

Key entities

  • company
    Haemonetics

    US‑listed medical‑technology firm (ticker HAE).

  • company
    CSL

    Global biotech and plasma products company.

Read at source← All news

StoryHaemonetics secures CSL Plasma rollout of NexSys PCS devices across U.S. centers by end‑2027

Also covered by

6 outlets

Related articles

$HAEMedAI 8/10

Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded

Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.

finance.yahoo.com
$HAEHighAI 8/10

Haemonetics Corporation Q2 2027 Earnings Call Summary

Haemonetics reported Q2 2027 plasma growth of 18%, driven by Persona PLUS adoption. CSL relationship expansion and FDA approval for PerQseal Elite were highlighted. Revenue guidance raised to 6-9%, but margin expansion lowered due to supply chain costs. Free cash flow conversion expected to exceed 80%.

finance.yahoo.com
$HAEMedAI 8/10

Haemonetics (HAE) Q2 2027 Earnings Call Transcript

Haemonetics reported Q2 2027 earnings, highlighting 6% organic growth in MedSurg and 14% in Apheresis. Key drivers include TEG 6s disposables, VASCADE products, and Persona PLUS adoption. The company raised its fiscal 2027 revenue guidance to 6%-9% organic growth and 8%-11% reported growth, citing strong first-half performance and increased visibility into customer commitments.

finance.yahoo.com
$HAEMed

Mizuho raises Haemonetics stock price target on plasma strength

Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.

investing.com
$HAEHighAI 8/10

BTIG raises Haemonetics stock price target to $142 on earnings beat

BTIG raised its price target on Haemonetics (HAE) to $142 from $130, maintaining a Buy rating. HAE's Q2 2027 revenue was $357.8M, up 9.3% YoY, beating estimates. Adjusted EPS was $1.35, exceeding expectations. All segments performed well, with Apheresis revenue at $204.8M. Adjusted gross margin increased to 61.9%. HAE raised fiscal 2027 revenue guidance but reduced adjusted EBIT margin expansion outlook.

investing.com